For the quarter ending 2025-09-30, SLS had $19,023K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,791 | -12,414 |
| Non-cash stock-based compensation | 503 | 1,006 |
| Non-cash lease expense | 147 | 296 |
| Prepaid expenses and other assets | 635 | 1,423 |
| Accounts payable | -1,031 | -164 |
| Accrued expenses and other current liabilities | 897 | -3,383 |
| Operating lease liabilities | -158 | -318 |
| Net cash used in operating activities | -7,068 | -16,400 |
| Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs | 0 | 23,051 |
| Proceeds from warrant inducement, net of issuance costs | 22,027 | - |
| Proceeds from the exercise of common stock warrants | 4,000 | 4,712 |
| Proceeds from employee stock purchases | 64 | 48 |
| Net cash provided by financing activities | 26,091 | 27,811 |
| Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents | 19,023 | 11,411 |
| Cash and cash equivalents at beginning of period | 13,986 | - |
| Cash and cash equivalents at end of period | 44,420 | - |
SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. (SLS)